(Q53312448)

English

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.

scientific article published on 15 July 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

0 references

1 reference

based on heuristic

inferred from title

polycythemia vera

1 reference

based on heuristic

inferred from title

Francesco Passamonti

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

3

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

author name string

E Rumi

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

C Elena

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

E Boveri

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

E Roncoroni

7

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

C Astori

8

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

M Merli

9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

S Boggi

10

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

C Pascutto

11

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

M Lazzarino

12

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

M Cazzola

13

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

publication date

15 July 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

24

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

1574-1579

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

https://scigraph.springernature.com/pub.10.1038/leu.2010.148

0 references

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

21 January 2018

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular and neoplastic risk in a large cohort of patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of low-dose aspirin in polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical relevance of JAK2 (V617F) mutant allele burden

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

How I treat patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Leukemic transformation of polycythemia vera: a single center study of 23 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.148

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2010.148

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20631743

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53312448&oldid=1531435735"